Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 3/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 7/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14348200 | 0.84 | MTNR1A (0.42) | MTNR1AMTNR1BPGR | |
| SCHEMBL27203790 | 0.84 | MTNR1A (0.42) | MTNR1AMTNR1BPGR | |
| SCHEMBL27203853 | 0.81 | MTNR1A (0.40) | PYGLMTNR1AMTNR1BPGR | |
| SCHEMBL24011024 | 0.80 | CNR1 (0.50) | PYGLCNR1MAPK14MTNR1AMTNR1B | |
| SCHEMBL14142980 | 0.79 | LMNA (0.39) | MAPK14MTNR1AMTNR1BPGR | |
| SCHEMBL10818656 | 0.78 | MEN1 (0.43) | MAPK1 | |
| SCHEMBL6198595 | 0.77 | CNR1 (0.48) | PYGLCNR1MAPK14MTNR1AMTNR1B | |
| SCHEMBL29854613 | 0.76 | EPHX2 (0.44) | MTNR1AMTNR1BPGR | |
| SCHEMBL26763722 | 0.76 | CNR1 (0.47) | PYGLCNR1MAPK14MTNR1AMTNR1B | |
| SCHEMBL19200342 | 0.75 | MAPT (0.54) | PYGLCNR1MTNR1AMTNR1BMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312214-B2 | 1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | QIAO JENNIFER X | 2007-06-14 | — | — | US | disclosed |
| US-7205318-B2 | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | F12, F2, PEPD | PYGL 2068/4885CNR1 4012/4885MAPK14 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.